Search Results
MC# 21-16
A Phase II Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor
MC# 21-22
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-Fluorouracil + Leucovorin in advanced pancreatic cancer
MC# 21-28
A Phase I/II Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
MC# 21-35
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer
MC# 22-21
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
MC# 22-27
A Phase I, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
MC# 22-38
A Phase II Study of CTX-009 in Adult Patients with Metastatic Colorectal Cancer who have received Two or Three Prior Systemic Chemotherapy Regimens
MC# 20-23
An Open-label, Multicenter Phase I/II Dose Escalation and Expansion Study of THOR 707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors
MC# 20-26
Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
MC# 21-04
BETA-PRIME: A Phase I/II, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors
MC# 21-12
An Exploratory Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy
MC# 21-15
An Open-Label, Phase I/II Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients with Advanced Solid Tumors
MC# 21-21
A Phase Ib/II, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination with ERAS-601 (SHP2 Inhibitor) to Patients with Advanced or Metastatic Solid Tumors
MC# 21-25
An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations
MC# 21-27
A Phase Ia/Ib, Open-label, Multicentre Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination with Other Anti-cancer Therapies in Patients with Advanced or Metastatic Solid Tumours Expressing KRAS G12C Mutation
MC# 21-29
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
MC# 21-41
A Phase I/II Study of ASP1570 in Participants with Locally Advanced or Metastatic Solid Tumors
MC# 21-42
A Phase I Study of The Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
MC# 22-02
A First-in-human, Phase I/II, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination with PARP Inhibitor Senaparib in Patients with Advanced Solid Tumors
MC# 22-04
A Phase I Study of BAL0891 as Monotherapy and in Combination with Chemotherapy in Patients with Advanced Solid Tumors
MC# 22-12
A Phase I, First in Human, Dose-Escalation Study of UCT-01-097 in Participants with Advanced Solid Tumors
MC# 22-13
A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors
MC# 22-20
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors
MC# 22-29
A Phase I, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors
MC# 23-02
A First-in-Human, Open-Label, Multi-Center Phase I Study of TST003 in Subjects with Locally Advanced or Metastatic Solid Tumors
